Vascular endothelial growth factor gene therapy - Biosidus S.A.

Drug Profile

Vascular endothelial growth factor gene therapy - Biosidus S.A.

Alternative Names: VEGF GENE Therapy - Biosidus S.A.

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Biosidus S.A.
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Vascular endothelial growth factor A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ischaemic heart disorders

Most Recent Events

  • 21 Jan 2016 Phase-I development is ongoing in Argentina
  • 17 Sep 2013 Phase-I clinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)
  • 17 Sep 2013 Preclinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top